Gilead Sciences Announces Third Quarter 2026 Financial Results

Gilead Sciences reported third-quarter 2026 revenue of $8.30 billion and adjusted EPS of $2.55, exceeding FactSet estimates of $7.81 billion and $2.19. CEO Daniel O’Day said base-business growth was the company’s strongest year over year in more than a decade. Gilead raised its full-year base-business revenue guidance, citing continued strength in its core portfolio.